nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.06.2004

FDG-PET in monitoring therapy of breast cancer

verfasst von: H.-J. Biersack, H. Bender, H. Palmedo

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Sonderheft 1/2004

Einloggen, um Zugang zu erhalten

Abstract

Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been used successfully for the staging and re-staging of breast cancer. Another significant indication is the evaluation of therapy response. Only limited data are available on the use of FDG-PET in breast cancer after radiation therapy. The same holds true for chemotherapy. Only the therapy response in locally advanced breast cancer after chemotherapy has been investigated thoroughly. Histopathological response could be predicted with an accuracy of 88–91% after the first and second courses of therapy. A quantitative evaluation is, of course, a prerequisite when FDG-PET is used for therapy monitoring. Only a small number of studies have focussed on hormone therapy. In this context, a flare phenomenon with increasing standardised uptake values after initiation of tamoxifen therapy has been observed. More prospective multicentre trials will be needed to make FDG-PET a powerful tool in monitoring chemotherapy in breast cancer.

Biersack HJ, Palmedo H, Bender H, Krause T. Nuclear medicine and breast cancer. In: Freeman LM, ed. Nuclear medicine annual 2001. Philadelphia: Lippincott Williams & Wilkins; 2001:69–108.

Kostakoglu L, Goldsmith SJ.¹⁸F-FDG-PET evaluation of the response to therapy for lymphoma and for breast, lung and colorectal carcinoma. J Nucl Med 2003; 44:224–239.PubMed

Grahek D, Montravers F, Kerrou K, Aide N, Lotz JP, Talbot JN. [¹⁸F]FDG in recurrent breast cancer: Diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nucl Med Mol Imaging 2004; 31:179–188.CrossRef

Biersack HJ, Palmedo H. Locally advanced breast cancer: Is PET useful for monitoring primary chemotherapy? J Nucl Med 2003; 44:1815–1817.PubMed

Haberkorn U, Reinhardt M, Strauss LG. Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy. J Nucl Med 1987; 33:1981–1987.

Minn H, Soini I. (¹⁸F)Fluorodeoxyglucose scintigraphy in diagnosis and follow-up of treatment in advanced breast cancer. Eur J Nucl Med Mol Imaging 1989; 15:61–66.

Lowe VJ. PET in radiotherapy. In: Oehr P, Biersack HJ, Coleman RE, eds. PET and PET-CT in oncology. Berlin Heidelberg New York: Springer; 2003:303–308.

Bockisch A, Freudenberg L, Antoch G, Müller S. PET/CT: clinical considerations. In: Oehr P, Biersack HJ, Coleman RE, eds. PET and PET-CT in oncology. Berlin Heidelberg New York: Springer; 2003:101–125.

Jones DN, McCowage GW, Soestman HD, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG-PET. J Nucl Med 1996; 37:1438–1444.PubMed

10.

Vranjesevic D, Filmont JE, Meta J, et al. Whole body (¹⁸F)-FDG-PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 2002; 43:325–329.PubMed

11.

Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995; 13:1470–1477.PubMed

12.

Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemo-hormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 1993; 11:2101–2111.PubMed

13.

Gennari A, Donati S, Salvadori B et al. Role of 2-(¹⁸F)-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000; 1:156–161.PubMed

14.

Tiling R, Linke R, Untch M, et al.¹⁸F-FDG-PET and ^99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study. Eur J Nucl Med Mol Imaging 2001; 28:711–720.CrossRef

15.

Krak NC, van der Hoeven JJ, Hoekstra OS, et al. Measuriing [¹⁸F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods. Eur J Nucl Med Mol Imaging 2003; 30:674–681.PubMed

16.

Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15:2483–2493.PubMed

17.

Booser DJ, Hortobagyi GN. Treatment of locally advanced breast cancer. Semin Oncol 1992; 19:278–285.PubMed

18.

Machiavelli M, Romero A, Pérez K, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998; 4:125–131.PubMed

19.

Chollet P, Charrier S, Brain E, et al. Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 1997; 3:862–866.CrossRef

20.

Vinnicombe SJ, MacVicar AD, Guy RL, et al. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology 1996; 198:333–340.PubMed

21.

Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002; 43:500–509.

22.

Palmedo H. What can we expect from MDR breast cancer imaging with sestamibi? J Nucl Med 2002; 43:526–529.PubMed

23.

Sagar SM, Klassen GA, Barclay KD, Aldrich JE. Antitumor treatment: tumor blood flow—measurement and manipulation for therapeutic gain. Cancer Treat Rev 1993; 19:299–349.PubMed

24.

Wilson CBJH, Lammertsma AA, McKienzie CG, Sikora K, Johns T. Measurement of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and non-invasive dynamic method. Cancer Res 1992; 52:1592–1597.PubMed

25.

Mankoff DA, Dunnwald LK, Gralow JR, et al. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using (technetium-99m)-sestamibi scintimammography. Cancer 1999; 85:2410–2423.CrossRefPubMed

26.

Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994; 13:139–168.PubMed

27.

Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer (LABC) treated with neo-adjuvant chemotherapy. J Nucl Med 2003; 44:1806–1814.PubMed

28.

Bassa P, Kim EE, Inoue T et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996; 37:931–938.PubMed

29.

Schelling M, Avril N, Nährig J, et al. Positron emission tomography using [¹⁸F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18:1689–1695.PubMed

30.

Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [¹⁸F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18:1676–1688.PubMed

31.

Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol 2002; 27:683–687.CrossRef

32.

Bender H, Bangard M, Metten N, et al. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. Hybridoma 1999; 18:87–91.PubMed

33.

McGuire AH, Dehdashti F, Siegel BA, et al. Positron tomographic assessment of 16α-[¹⁸F]fluoro-17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991; 32:1526–1531.PubMed

34.

Jonson SD, Welch MJ. PET imaging of breast cancer with fluorine-18 radiolabelled estrogens and progestins. Q J Nucl Med 1998; 42:8–17.PubMed

35.

Inoue T, Kim EE, Wallace S, et al. Positron emission tomography using [¹⁸F}fluoro-tamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm 1996; 11:235–245.PubMed

36.

Dehdashti F, Flanagan FL, Mortimer JE, et al. Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999; 26:51–56.CrossRefPubMed

Titel: FDG-PET in monitoring therapy of breast cancer
verfasst von: H.-J. Biersack
H. Bender
H. Palmedo
Publikationsdatum: 01.06.2004
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe Sonderheft 1/2004
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-004-1533-x

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

FDG-PET in monitoring therapy of breast cancer

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2004

Use of tomographic nuclear medicine procedures, SPECT and pinhole SPECT, with cationic lipophilic radiotracers for the evaluation of axillary lymph node status in breast cancer patients

153Sm-EDTMP for bone pain palliation in skeletal metastases

The choice of the correct imaging modality in breast cancer management

FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer

State of the art of current modalities for the diagnosis of breast lesions

FDG-PET for axillary lymph node staging in primary breast cancer